Logo image of NRX.CA

NUREXONE BIOLOGIC INC (NRX.CA) Stock Overview

Canada - TSX-V:NRX - CA67059R1091 - Common Stock

1.05 CAD
+0.05 (+5%)
Last: 9/22/2025, 7:00:00 PM

NRX.CA Key Statistics, Chart & Performance

Key Statistics
52 Week High1.14
52 Week Low0.53
Market Cap85.55M
Shares81.48M
Float76.91M
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-0.13
PEN/A
Fwd PEN/A
Earnings (Next)N/A N/A
IPO05-08 2012-05-08
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology


NRX.CA short term performance overview.The bars show the price performance of NRX.CA in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 10 20 30 40 50

NRX.CA long term performance overview.The bars show the price performance of NRX.CA in the last 1, 2 and 3 years. 1 year 2 years 3 years 100 200 300

The current stock price of NRX.CA is 1.05 CAD. In the past month the price increased by 26.51%. In the past year, price increased by 84.21%.

NUREXONE BIOLOGIC INC / NRX Daily stock chart

NRX.CA Competitors/Peers

The largest stocks on the Canadian markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
EDT.CA SPECTRAL MEDICAL INC N/A 411.58M
FRX.CA FENNEC PHARMACEUTICALS INC N/A 336.19M
EPRX.CA EUPRAXIA PHARMACEUTICALS INC N/A 318.97M
TH.CA THERATECHNOLOGIES INC N/A 210.59M
HBP.CA HELIX BIOPHARMA CORP N/A 118.39M
BLU.CA BLUENERGIES LTD N/A 107.78M
WLLW.CA WILLOW BIOSCIENCES INC N/A 100.71M
MDNA.CA MEDICENNA THERAPEUTICS CORP N/A 83.41M
MSCL.CA SATELLOS BIOSCIENCE INC N/A 67.23M
COV.CA COVALON TECHNOLOGIES LTD 17 60.60M
SVA.CA SERNOVA BIOTHERAPEUTICS INC N/A 45.90M
MBX.CA MICROBIX BIOSYSTEMS INC N/A 37.04M

About NRX.CA

Company Profile

NRX logo image NurExone Biologic, Inc. is a pharmaceutical company, which engages in the development and commercialization of biological extracellular vesicles-based technology drug platforms. The firm is engaged in developing a platform for biologically guided exosome-based therapies to be delivered, minimally invasive, to patients who have suffered central nervous system injuries. The Company’s first product, ExoPTEN for acute spinal cord injury, uses exosomes loaded with a specific and proprietary sIRNA sequence as the active pharmaceutical ingredient. Its ExoTherapy is a proprietary platform for developing exosome-based therapies. The NurExone platform technology is expected to offer solutions to drug companies interested in minimally invasive targeted drug delivery for other indications.

Company Info

NUREXONE BIOLOGIC INC

Minus 1 Entry, Ground Floor Of Bldg B

Haifa ALBERTA IL

Employees: 12

NRX Company Website

NRX Investor Relations

Phone: 972524803034

NUREXONE BIOLOGIC INC / NRX.CA FAQ

What is the stock price of NUREXONE BIOLOGIC INC today?

The current stock price of NRX.CA is 1.05 CAD. The price increased by 5% in the last trading session.


What is the ticker symbol for NUREXONE BIOLOGIC INC stock?

The exchange symbol of NUREXONE BIOLOGIC INC is NRX and it is listed on the TSX Venture Exchange exchange.


On which exchange is NRX.CA stock listed?

NRX.CA stock is listed on the TSX Venture Exchange exchange.


What is the price forecast or stock price prediction for NUREXONE BIOLOGIC INC stock?

9 analysts have analysed NRX.CA and the average price target is 3.12 CAD. This implies a price increase of 196.77% is expected in the next year compared to the current price of 1.05. Check the NUREXONE BIOLOGIC INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is NUREXONE BIOLOGIC INC worth?

NUREXONE BIOLOGIC INC (NRX.CA) has a market capitalization of 85.55M CAD. This makes NRX.CA a Micro Cap stock.


How many employees does NUREXONE BIOLOGIC INC have?

NUREXONE BIOLOGIC INC (NRX.CA) currently has 12 employees.


What are the support and resistance levels for NUREXONE BIOLOGIC INC (NRX.CA) stock?

NUREXONE BIOLOGIC INC (NRX.CA) has a support level at 0.99. Check the full technical report for a detailed analysis of NRX.CA support and resistance levels.


Should I buy NUREXONE BIOLOGIC INC (NRX.CA) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does NUREXONE BIOLOGIC INC (NRX.CA) stock pay dividends?

NRX.CA does not pay a dividend.


What is the Price/Earnings (PE) ratio of NUREXONE BIOLOGIC INC (NRX.CA)?

NUREXONE BIOLOGIC INC (NRX.CA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.13).


NRX.CA Technical Analysis

ChartMill assigns a technical rating of 10 / 10 to NRX.CA. When comparing the yearly performance of all stocks, NRX.CA is one of the better performing stocks in the market, outperforming 87.07% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

NRX.CA Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to NRX.CA. While NRX.CA seems to be doing ok healthwise, there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

NRX.CA Financial Highlights

Over the last trailing twelve months NRX.CA reported a non-GAAP Earnings per Share(EPS) of -0.13. The EPS decreased by -10.9% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -220.67%
ROE -412.53%
Debt/Equity 0.06
Chartmill High Growth Momentum
EPS Q2Q%-12.5%
Sales Q2Q%N/A
EPS 1Y (TTM)-10.9%
Revenue 1Y (TTM)N/A

NRX.CA Forecast & Estimates

9 analysts have analysed NRX.CA and the average price target is 3.12 CAD. This implies a price increase of 196.77% is expected in the next year compared to the current price of 1.05.


Analysts
Analysts84.44
Price Target3.12 (197.14%)
EPS Next Y0%
Revenue Next YearN/A

NRX.CA Ownership

Ownership
Inst OwnersN/A
Ins Owners5.89%
Short Float %N/A
Short RatioN/A